In­side Bio­gen's scram­ble to sell Aduhelm: Project 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

In an­tic­i­pa­tion of Aduhelm’s ap­proval for Alzheimer’s in June, Bio­gen em­ploy­ees were di­rect­ed to iden­ti­fy and guar­an­tee treat­ment cen­ters would ad­min­is­ter the drug through a pro­gram called “Javelin,” a se­nior Bio­gen em­ploy­ee told End­points News.

The pro­gram iden­ti­fied about 800 cen­ters for use, he said, and Bio­gen now pays for the use of bioas­says to iden­ti­fy be­ta amy­loid in po­ten­tial pa­tients hav­ing un­der­gone a lum­bar punc­ture pro­ce­dure, the em­ploy­ee said — and one cen­ter prepar­ing to ad­min­is­ter the drug con­firmed its par­tic­i­pa­tion in the bioas­say pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER